ClinicalTrials.gg
CompletedNCT02701309IronKidsUpdated Sep 8, 2016

Non-invasive Optical Detection of Iron Deficiency in Children

An observational study in Iron Deficiency, Iron-deficiency Anemia and Child, sponsored by Ludwig-Maximilians - University of Munich. Completed at 2 sites in Germany. Open to participants aged 9 Months to 5 Years. Per ClinicalTrials.gov, last updated 2016-09-08.

Sponsored by Ludwig-Maximilians - University of Munich · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
9 Months to 5 Years
Sex
All
01

Study summary

This study aims to evaluate a prototype device detecting zinc protoporphyrin-IX fluorescence non-invasively from the intact oral mucosa in children. The prototype device has shown high sensitivity and specificity in women after delivery for iron deficiency. Children are at increased risk for iron deficiency and prevention methods are not established jet. Zinc protoporphyrin-IX is an early indicator of iron deficiency and may be more sensitive than other established parameters. The prototype device is used to measure the erythrocyte zinc protoporphyrin-IX/heme ratio in children aged 9 months to 5 years. Children in this age are at increased risk for iron deficiency as they are growing rapidly and iron deficiency in this age may affect the neurodevelopment and immune system adversely. It is proposed that these effects cannot be rectified by iron supplementation in later years. The results from the non-invasive measurements are compared to reference measurements of the erythrocyte zinc protoporphyrin-IX/heme ratio from residual blood samples from the same patients and to other indicators of iron status, including hemoglobin, ferritin, serum iron, transferrin, transferrin saturation and soluble transferrin receptor.

Read the detailed description

This trial is a proof-of-concept study using a prototype fiber optic fluorometer to acquire autofluorescence spectra in children aged 9 months to 5 years and determine the erythrocyte zinc protoporphyrin-IX fluorescence intensity from these spectra. The non-invasively determined fluorescence spectra are evaluated to provide a quantitative measure of the erythrocyte zinc protoporphyrin-IX/heme concentration ratio. These values are primarily compared to an erythrocyte zinc protoporphyrin-IX determined by HPLC from residual blood samples from the same subjects and secondarily to erythrocyte zinc protoporphyrin-IX/heme ratios determined using a commercial hematofluorometer (AVIV, model 206d) and other indicators of iron status, including hemoglobin, ferritin, serum iron, transferrin, transferrin saturation and soluble transferrin receptor

This study could help to establish the non-invasive fluorescence measurement of zinc protoporphyrin-IX as a rapid, easy to use means for point-of-care screening for iron deficiency in resource-limited settings lacking laboratory infrastructure.

02

Conditions studied

  • Iron Deficiency
  • Iron-deficiency Anemia
  • Child

Keywords

  • Iron deficiency
  • Child
  • Infancy
  • Preschool children
  • iron deficiency anemia
03

In context

Iron Deficiencies

782 studies on the registry are indexed under Iron Deficiencies; 114 are open to participants now.

This study's enrollment of 100 is below the median of 200 across 153 observational studies indexed under Iron Deficiencies.

Browse Iron Deficiencies studies →

Lead sponsor

Ludwig-Maximilians - University of Munich is the lead sponsor of 223 studies on the registry; 29 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
9 Months to 5 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Children aged 9 months to 5 years

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged 9 months to 5 years
  • Planed blood sampling, independently from this study
  • Informed written consent to participation´s guardian in the study

Exclusion criteria

Exclusion Criteria:

  • the ability of the guardian is not given to approve the consent
  • transfusion of blood products before entering the study
  • blood sampling is not planed for clinical investigations
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (actual)
Patient registry
No

Groups and cohorts

  • Non-invasive Iron detection

    Children between 9months and 5years will be recruited for a non-invasive iron measurement on the lower lip. This study is focusing on the feasability of a non-invasive detection method. There is no intervention planed. The device is tested once for 3-5 Minutes.

    Device: Non-invasive Iron detection device via Zinc-Protoporphyrin

Interventions

  • DeviceNon-invasive Iron detection device via Zinc-Protoporphyrin

    In this study the feasability, sensitivity and specifity of a non-invasive detection method of zinc-protoporphyrin in children is evaluated. It´s a one-arm study, without control Group. Children are aged between 9m and 5y and have a clinical blood sampling indicated.

    Also known as: Iron detection device

06

What researchers measure

Primary outcomes

  1. Comparison of non-invasive erythrocyte zinc protoporphyrin IX measurements with HPLC reference (Spearman's Rho correlation, sensitivity and specificity)

    Erythrocyte zinc protoporphyrin IX in the units of μmol/mol heme, as determined from non-invasive fluorescence and remission spectroscopic measurements at the oral mucosa, compared with reference standard determinations of erythrocyte zinc protoporphyrin IX in blood samples by high performance liquid chromatography (HPLC).

    Time frame: 1 day after measurement

Secondary outcomes

  1. Comparison of non-invasive erythrocyte zinc protoporphyrin IX measurements with estimate of body iron (sensitivity and specificity)

    Erythrocyte zinc protoporphyrin IX in the units of μmol/mol heme, as determined from non-invasive fluorescence and remission spectroscopic measurements at the oral mucosa, compared with an estimate of total body iron, determined from the logarithm of the soluble transferrin receptor/ferritin ratio.

    Time frame: 1 day after measurement

07

Study locations

2 sites
  • Div. Metabolic and Nutritional Medicine Dr. von Hauner Children's Hospital Univ. of Munich Medical Centre
    Munich, Bavaria 80337, Germany
  • LMU Munich
    Munich, Bavaria 80337, Germany
08

References and documents

Individual participant data

Plan to share: Undecided — The principal investigator (PI, Prof. Dr. Dr. B. Koletzko) has access to the study data. The data may be shared with other researchers for specific research purposes if a written request with detailed description of objectives and goals, workplan and statistical analysis plan, strategy to protect data from other uses, publication strategy, and description of the research team and its qualification is provided. Based on the evaluation of proposals, the PI and study team will decided on a case by case basis which data can be provided.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2016, a primary completion of Sep 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2016
First posted
Mar 8, 2016
Start
Apr 2016
Primary completionActual
Sep 2016
CompletionActual
Sep 2016
Last update
Sep 8, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02701309
Responsible party
Koletzko - Office (Prof. Dr., Ludwig-Maximilians - University of Munich) — Principal investigator
First posted
Mar 8, 2016
Start date
Apr 2016
Primary completion
Sep 2016
Completion
Sep 2016
Last update
Sep 8, 2016

Study contacts

Berthold Koletzko, Prof.Dr.med.
principal investigator · LMU Munich, Germany

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion